KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Gains from Investment Securities (2020 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Gains from Investment Securities for 6 consecutive years, with -$9.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities fell 5073.54% year-over-year to -$9.4 million, compared with a TTM value of $9.6 million through Sep 2025, up 903.03%, and an annual FY2024 reading of -$31000.0, down 102.05% over the prior year.
  • Gains from Investment Securities was -$9.4 million for Q4 2025 at Aurinia Pharmaceuticals, down from $8.3 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $11.9 million in Q2 2023 and bottomed at -$9.4 million in Q4 2025.
  • Average Gains from Investment Securities over 5 years is $1.3 million, with a median of $189000.0 recorded in 2024.
  • The sharpest move saw Gains from Investment Securities surged 2080.03% in 2023, then plummeted 9270.59% in 2024.
  • Year by year, Gains from Investment Securities stood at -$666000.0 in 2021, then surged by 190.24% to $601000.0 in 2022, then soared by 95.67% to $1.2 million in 2023, then tumbled by 83.93% to $189000.0 in 2024, then crashed by 5073.54% to -$9.4 million in 2025.
  • Business Quant data shows Gains from Investment Securities for AUPH at -$9.4 million in Q4 2025, $8.3 million in Q3 2025, and $1.1 million in Q2 2025.